Core Insights - Corxel Pharmaceuticals has raised $287 million in a Series D1 funding round to advance its obesity drug CX11 into further testing [8] - The financing reflects a trend among drugmakers and biotech investors in the U.S. and Europe to license drugs discovered in China, with successful acquisitions already seen in the market [3][4] - CX11, an oral GLP-1 therapy, is positioned as a differentiated treatment that could provide weight reduction comparable to injectable GLP-1 medications [6] Industry Trends - There is a growing interest in obesity treatments, with startups like Kailera Therapeutics and Verdiva Bio emerging around weight loss drugs developed in China [5] - The FDA's recent approval of an oral form of Wegovy indicates a strong market demand for oral obesity medications, with initial prescription numbers showing a fast start [7] - Corxel plans to conduct a global Phase 2 study for type 2 diabetes this year and is preparing for additional late-stage trials [8]